VTVT - CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19 | Benz
WESTON, Fla. and ANN ARBOR, Mich., Sept. 27, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, and Michigan Medicine, a part of the University of Michigan and one of the nation's leading academic medical centers, announced today the initiation of a randomized, double-blind, placebo-controlled, multicenter, Phase 3 pivotal clinical trial to evaluate the safety and efficacy of Cantex's azeliragon in decreasing the incidence of acute kidney injury and other life-threatening complications in patients hospitalized for COVID-19. The initiation of this Phase 3 pivotal clinical trial follows the completion of the Phase 2 portion of the clinical trial.
Cantex's azeliragon is an orally administered inhibitor of the receptor for advanced glycation end products (known as RAGE). Excessive activation of RAGE has been strongly implicated in life-threatening complications of COVID-19 infection, including lung and kidney failure. In addition, high levels of "suPAR," a protein produced by the immune system, predisposes patients ...